Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Concert Pharmaceuticals, Inc. (NASDAQ: CNCE).

Full DD Report for CNCE

You must become a subscriber to view this report.


Recent News from (NASDAQ: CNCE)

Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q1 2018 Results - Earnings Call Transcript
Concert Pharmaceuticals, Inc. (CNCE) Q1 2018 Earnings Conference Call May 03, 2018, 08:30 ET Executives Justine Koenigsberg - SVP, Corporate Communications and IR Roger Tung - Co-Founder, CEO, President & Director James Cassella - Chief Development Officer Marc Becker - CFO...
Source: SeekingAlpha
Date: May, 06 2018 01:23
Concert Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Concert Pharmaceuticals, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 04 2018 13:55
Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
Conference Call Scheduled Today at 8:30 a.m. EDT Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018. “Concert has begun 2018 with strong momentum as our pipeline of first-in-class drug candidates for serious disea...
Source: Business Wire
Date: May, 03 2018 07:00
Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis
Recently, Vertex Pharmaceuticals ( VRTX ) announced an update on one of its programs dealing with a triple-combo treatment for cystic fibrosis. It was announced that a phase 3 triple-combo dealing with VX-561 would be put on hold on safety concerns . This is somewhat bad news for Vertex, ...
Source: SeekingAlpha
Date: April, 30 2018 07:17
Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial...
Source: Business Wire
Date: April, 26 2018 07:00
Concert Pharma completes enrollment in mid-stage study of CTP-543 in autoimmune-related hair loss
Enrollment has been completed in a Phase 2a clinical trial evaluating Concert Pharmaceuticals' (NASDAQ: CNCE ) CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles resulting in hair loss. The primary endpoin...
Source: SeekingAlpha
Date: April, 25 2018 07:56
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Topline Phase 2a Data from the 4 mg and 8 mg Cohorts Expected in Fourth Quarter of 2018 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia a...
Source: Business Wire
Date: April, 25 2018 07:00
Research Report Identifies Signature Bank, Concert Pharmaceuticals, Easterly Government Properties, Hilltop, Columbia Banking System, and New Jersey Resources with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Signature Bank (NASDAQ:SBNY), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE...
Source: GlobeNewswire
Date: April, 23 2018 07:35
By The Numbers: Best Biotech Stocks
Investing in biotech stocks can be a double-edged sword. When positioned in the right biotech names, investors can be rewarded with massive gains. On the other hand, the losses are also substantial if you pick the wrong stocks in the sector. There is no infallible formula to picking winning ...
Source: SeekingAlpha
Date: April, 05 2018 06:47
Concert Therapeutics Will See A Second Wind In Coming Months
Concert Therapeutics ( CNCE ) is a great long opportunity for investors in the biotechnology industry. The small-cap company has seen a 32% rise in the past year, but potential longs should not consider the opportunity missed. A brief look into Concert's pipeline and financial structure wi...
Source: SeekingAlpha
Date: April, 02 2018 10:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1820.5320.4720.8520.32221,407
2018-05-1720.5320.4720.8520.32221,407
2017-09-1315.1314.9015.1314.8178,800
2017-09-1215.2514.9515.5314.825194,868
2017-09-1115.3614.6715.4514.51111,226

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-243,63520,92217.3741Cover
2018-05-234,72221,21622.2568Cover
2018-05-227,77124,03332.3347Cover
2018-05-213,65914,27525.6322Cover
2018-05-185,71124,41223.3942Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CNCE.


About Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Logo for Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $449,667,584 - 05/11/2018
  • Issue and Outstanding: 23,395,816 - 05/01/2018

 


Recent Filings from (NASDAQ: CNCE)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 22 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (NASDAQ: CNCE)

Daily Technical Chart for (NASDAQ: CNCE)


Stay tuned for daily updates and more on (NASDAQ: CNCE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CNCE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CNCE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CNCE and does not buy, sell, or trade any shares of CNCE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/